8F0E | pdb_00008f0e

N-terminal WD40 domain of beta'-COPI subunit with four chains in the asymmetric unit


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.31 Å
  • R-Value Free: 
    0.191 (Depositor), 0.195 (DCC) 
  • R-Value Work: 
    0.157 (Depositor), 0.162 (DCC) 
  • R-Value Observed: 
    0.159 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 8F0E

This is version 1.2 of the entry. See complete history

Literature

Strategies for rapid production of crystallization quality coatomer WD40 domains.

Dey, D.Hasan, S.S.

(2023) Protein Expr Purif 212: 106358-106358

  • DOI: https://doi.org/10.1016/j.pep.2023.106358
  • Primary Citation Related Structures: 
    8EVL, 8EWX, 8F0E

  • PubMed Abstract: 

    The vesicular secretion of soluble cargo proteins from the endoplasmic reticulum (ER) is accompanied by the export of ER-resident membrane proteins that are co-packaged in secretory vesicles. The cytosolic coatomer protein complex I (COPI) utilizes the N-terminal WD40 domains of α-COPI and β'-COPI subunits to bind these membrane protein "clients" for ER retrieval. These "αWD40" and "β'WD40" domains are structural homologs that demonstrate distinct selectivity for client proteins. However, elucidation of the atomic-level principles of coatomer-client interactions has been challenging due to the tendency of αWD40 domain to undergo aggregation during expression and purification. Here we describe a rapid recombinant production strategy from E. coli, which substantially enhances the quality of the purified αWD40 domain. The αWD40 purification and crystallization are completed within one day, which minimizes aggregation losses and yields a 1.9 Å resolution crystal structure. We demonstrate the versatility of this strategy by applying it to purify the β'WD40 domain, which yields crystal structures in the 1.2-1.3 Å resolution range. As an alternate recombinant production system, we develop a cost-effective strategy for αWD40 production in human Expi293 cells. Finally, we suggest a roadmap to simplify these protocols further, which is of significance for the production of WD40 mutants prone to rapid aggregation. The WD40 production strategies presented here are likely to have broad applications because the WD40 domain represents one of the largest families of biomolecular interaction modules in the eukaryotic proteome and is critical for trafficking of host as well as viral proteins such as the SARS-CoV-2 spike protein.


  • Organizational Affiliation
    • Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.

Macromolecule Content 

  • Total Structure Weight: 137.52 kDa 
  • Atom Count: 10,922 
  • Modeled Residue Count: 1,187 
  • Deposited Residue Count: 1,208 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Coatomer subunit beta'
A, B, C, D
302Saccharomyces cerevisiaeMutation(s): 0 
UniProt
Find proteins for P41811 (Saccharomyces cerevisiae (strain ATCC 204508 / S288c))
Explore P41811 
Go to UniProtKB:  P41811
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP41811
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.31 Å
  • R-Value Free:  0.191 (Depositor), 0.195 (DCC) 
  • R-Value Work:  0.157 (Depositor), 0.162 (DCC) 
  • R-Value Observed: 0.159 (Depositor) 
Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 49.115α = 90
b = 89.945β = 93.76
c = 138.324γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
XDSdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Department of Energy (DOE, United States)United StatesDE-SC0012704
National Institutes of Health/National Cancer Institute (NIH/NCI)United StatesP30CA134274

Revision History  (Full details and data files)

  • Version 1.0: 2023-08-30
    Type: Initial release
  • Version 1.1: 2023-10-04
    Changes: Database references
  • Version 1.2: 2026-03-04
    Changes: Refinement description, Structure summary